Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Non-Current Assets (2016 - 2025)

VYNE Therapeutics' Non-Current Assets history spans 10 years, with the latest figure at $150000.0 for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 93.92% year-over-year to $150000.0; the TTM value through Dec 2025 reached $150000.0, down 93.92%, while the annual FY2025 figure was $150000.0, 93.92% down from the prior year.
  • Non-Current Assets reached $150000.0 in Q4 2025 per VYNE's latest filing, down from $375000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $6.1 million in Q1 2021 to a low of $150000.0 in Q4 2025.
  • Average Non-Current Assets over 5 years is $2.7 million, with a median of $2.5 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: surged 51.65% in 2024, then tumbled 93.92% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $3.9 million in 2021, then crashed by 35.67% to $2.5 million in 2022, then tumbled by 30.65% to $1.7 million in 2023, then soared by 43.32% to $2.5 million in 2024, then crashed by 93.92% to $150000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Non-Current Assets are $150000.0 (Q4 2025), $375000.0 (Q2 2025), and $1.5 million (Q1 2025).